Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
OHE at ISPOR Europe 2018
7 November 2018
Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 conference in Barcelona, 10-14 November.
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
5 November 2018
OHE presented at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare, held October 2018.
New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
12 October 2018
A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores…
OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer
4 October 2018
OHE will be hosting two lunchtime seminars in October – one on the 22nd with Steven Pearson, ICER, and another on the 31st with Janel Hanmer,…
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA)…
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.
Two New Papers on EQ-5D-5L Valuation in Ireland
21 August 2018
OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland.
NICE Recommendation Highlights Role of Social Value Judgements
9 August 2018
This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma. The…
Opportunity Costs of New Health Care Technologies: A Research Agenda
8 August 2018
A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.